Choosing a China hospital for DLBCL: match the center to the clinical task

Choose a DLBCL hospital by the clinical task it needs to accomplish. Routine first-line care, disputed pathology, early-relapse CAR T assessment, salvage followed by transplantation and a trial require overlapping but different expertise. Reputation, equipment counts and one successful case cannot establish suitability for an individual's stage of treatment. [S1,S3]

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

A newly diagnosed patient may need integrated pathology, staging and a first-line plan. A disputed report calls for hematopathology review. Relapse may require an assessment of transplantation, CAR T cells or another feasible path. A general question about whether the hospital treats lymphoma cannot establish the required scope.
Localized strategies and uncertain residual sites benefit from joint interpretation by hematology, nuclear medicine and radiation oncology. Ask whether pretreatment DICOM is available, who decides on additional biopsy and whether the radiation goal is consolidation, local salvage or symptom relief. [S3,S18]
Before arrival, obtain the responsible department, visit purpose, required material, provisional assessment sequence, financial scope and contacts. The regimen may change after new results, but someone must explain and track the change. Patients do not need a prediction of every event; they need clear responsibility when events occur.

Quick answer

Full guide

International patients also need timely acceptance, urgent fever care, continuous cycles and a home-country handover. These practical matters affect whether treatment can proceed. Review records and receiving arrangements remotely when possible before travel; unstable illness should first be managed locally.

Begin with a specific request

A newly diagnosed patient may need integrated pathology, staging and a first-line plan. A disputed report calls for hematopathology review. Relapse may require an assessment of transplantation, CAR T cells or another feasible path. A general question about whether the hospital treats lymphoma cannot establish the required scope.

Send a one-page summary with the full diagnosis, dates, treatment lines, current symptoms, organ problems and the question to resolve. Ask what additional records are needed, which department takes responsibility and what the first visit is intended to achieve. A center cannot reliably promise an outcome before reviewing the case. [S1]

Check how pathology is reviewed

DLBCL must be distinguished from specific large B-cell entities, and protein expression must not be confused with gene rearrangement. Ask about hematopathology review, access to original slides or blocks, necessary staining and FISH, and responsibility for the integrated report. [S2,S3]

External testing is not automatically a disadvantage if specimen handling, turnaround and responsibility are clear. The hospital should explain when existing material is sufficient and when repeat biopsy is necessary. Its ability to coordinate adequate diagnosis with timely care is especially relevant when the lymphoma is progressing quickly.

Expect first-line care to cover the full cycle

Delivering R-CHOP or Pola-R-CHP involves pharmacy checks, cardiac and infection assessment, steroid and supportive prescriptions, blood-count monitoring and adjustment. A course can span months. If the institution offers only a consultation, identify where continuing care will occur. [S1,S4]

Ask which risk and stage features justify the recommendation, whether radiation is anticipated and when response will be assessed. Explaining why an additional treatment is unnecessary can be part of good care. The ability to add many new drugs is not the only meaningful measure of competence.

Look for a clear relapse decision process

Refractory or early relapsed disease may lead to early CAR T evaluation, while selected later, salvage-sensitive relapse may support autologous transplantation. The center should use repeat pathology, timing, organ function and infection rather than recommend the same costly procedure to every referral. [S5,S13]

Ask who may be declined temporarily or permanently, who manages disease during waiting and what alternatives follow an unsuccessful assessment. Technical capability does not prove individual suitability. If several treatments are proposed before the main procedure, understand their objectives and effects on later options.

Verify toxicity management for cellular and bispecific treatment

The center should describe monitoring for cytokine release syndrome, neurological toxicity, infection and prolonged cytopenias, including access to intensive care and relevant specialists. CAR T collection, manufacturing, lymphodepletion and infusion also require coordination. [S6,S7,S11]

One infusion does not mean a brief ordinary outpatient service. Ask about admission or nearby residence, caregiver requirements, overnight contacts and travel clearance. Product and patient differences affect these arrangements. Changes to foreign administrative requirements should not be treated as evidence that clinical risks have disappeared.

Use official department pages as consultation starting points

Peking University Cancer Hospital's official site lists a lymphoma department and describes lymphoma, stem-cell transplantation and cellular-immunotherapy services. [S30] Sun Yat-sen University Cancer Center lists lymphoma within medical oncology, while its English directory includes hematological oncology, pathology, nuclear medicine, radiation oncology and intensive care. [S31,S32]

These are verifiable starting points, not a ranking or a guarantee of a particular medicine, trial place or immediate international acceptance. Send the same records to candidate centers and compare their clinical answers and practical conditions. Confirm the current campus and receiving process through official channels rather than forwarded contact details.

Assess coordination if radiation may be needed

Localized strategies and uncertain residual sites benefit from joint interpretation by hematology, nuclear medicine and radiation oncology. Ask whether pretreatment DICOM is available, who decides on additional biopsy and whether the radiation goal is consolidation, local salvage or symptom relief. [S3,S18]

Machine sophistication alone does not establish organ protection or plan quality. Request an explanation of the actual field, possible long-term concerns and follow-up arrangements. If radiation will occur elsewhere, clarify the transfer of images and responsibility so that neither team assumes the other completed an essential assessment.

Verify a trial at the actual site

Previous research participation does not prove current recruitment or international eligibility. Obtain the identifier, cohort, criteria and official contact, and provide prior medicines, transplantation or CAR T exposure, infection and organ information. The research team must confirm screening suitability. [S16,S17]

Ask about standard alternatives, extra procedures, withdrawal and cost responsibility. If no slot exists or screening fails, determine whether appropriate ordinary treatment can begin promptly. An unconfirmed research opportunity should not leave active lymphoma unmanaged during a prolonged overseas stay.

Make emergency support concrete

Ask which emergency department to use for fever, where weekend blood tests occur and who arranges transfusion or admission. The latest regimen, treatment date and allergies should be quickly available. Fever of 38°C or above, especially with chills, breathlessness or confusion, should not wait for a routine appointment. [S8]

Nutrition, pain, rehabilitation, fertility and psychological services may be in separate departments, but there should be a usable referral route. International coordinators can arrange administration; clinical decisions and medicine changes require appropriately qualified clinicians.

Check language support and record access

Pathology, combination treatment and informed consent require accurate translation. Ask about medical interpreting, written English summaries and bilingual prescriptions, including charges. A relative who handles ordinary conversation may not reliably interpret rearrangements or immune toxicity. Confirm that the patient understands the important choices.

Keep original tests, DICOM files, drug administration records and discharge summaries for review and home care. [S12] If documents are only viewable in an application, ask how to export them. Sharing usable records and explaining the rationale are requirements of continuity, not a sign that the patient distrusts the institution.

Compare like-for-like financial scope

Request a Chinese-yuan breakdown for diagnosis, drugs and dose assumptions, administration, beds, support, cellular or radiation stages, reassessment and possible extras. International self-pay and resident insurance figures may differ. No individualized hospital prices were verified for this article, so an institutional price ranking would be unsupported. [S10]

Clarify deposits, timing, cancellation, delay, manufacturing problems and complications. A lower amount omitting monitoring or later medicines cannot be compared directly with a fuller quotation. Include housing, caregiver leave and transport before choosing the city.

Match waiting time to clinical urgency

Stable patients seeking specialist review may reduce unnecessary travel through remote assessment. Rapid progression, respiratory problems, bleeding or severe cytopenias require appropriate local care first. Administrative appointment availability does not establish how long it is medically safe to wait. [S22]

Consider the route between accommodation, treatment and emergency services rather than flight convenience alone. Repeated visits make commuting and caregiver capacity important. Return travel should follow recovery and support assessment, not merely the end of an international-service booking.

Finish with named responsibilities

Before arrival, obtain the responsible department, visit purpose, required material, provisional assessment sequence, financial scope and contacts. The regimen may change after new results, but someone must explain and track the change. Patients do not need a prediction of every event; they need clear responsibility when events occur.

Ask about home-country handover while selecting the center: treatment summary, images, unresolved toxicity, communication with the home hematologist and locally deliverable follow-up. [S12] A suitable institution connects the immediate decision with continuing care rather than only completing an expert appointment.

A comparison sheet can record the same clinical questions for every candidate center, the date of its reply and the responsible department. Leave medicine supply, beds and research eligibility explicitly unconfirmed until the institution has answered. Do not turn a coordinator’s estimate into clinical acceptance. Keep the home-care contact active until the receiving arrangement is operational. If a second opinion differs, retain both explanations and ask whether they used the same pathology version and current imaging. This can reveal an information gap before it becomes an apparent disagreement about the best treatment.